Impax Asset Management Group plc lessened its stake in shares of CVS Health Corporation (NYSE:CVS - Free Report) by 14.0% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 379,107 shares of the pharmacy operator's stock after selling 61,872 shares during the quarter. Impax Asset Management Group plc's holdings in CVS Health were worth $25,684,000 at the end of the most recent quarter.
Other institutional investors have also recently made changes to their positions in the company. Hopwood Financial Services Inc. purchased a new stake in shares of CVS Health during the fourth quarter valued at approximately $29,000. McIlrath & Eck LLC boosted its stake in shares of CVS Health by 32.6% during the fourth quarter. McIlrath & Eck LLC now owns 707 shares of the pharmacy operator's stock valued at $32,000 after purchasing an additional 174 shares during the period. Park Square Financial Group LLC purchased a new stake in shares of CVS Health during the fourth quarter valued at approximately $43,000. PARK CIRCLE Co boosted its stake in shares of CVS Health by 42.9% during the fourth quarter. PARK CIRCLE Co now owns 1,000 shares of the pharmacy operator's stock valued at $45,000 after purchasing an additional 300 shares during the period. Finally, Strategic Investment Solutions Inc. IL lifted its stake in CVS Health by 77.2% in the fourth quarter. Strategic Investment Solutions Inc. IL now owns 1,024 shares of the pharmacy operator's stock worth $46,000 after acquiring an additional 446 shares during the period. Hedge funds and other institutional investors own 80.66% of the company's stock.
CVS Health Stock Up 1.2%
Shares of NYSE:CVS traded up $0.78 on Friday, hitting $67.38. 3,770,987 shares of the company traded hands, compared to its average volume of 10,851,185. CVS Health Corporation has a 52 week low of $43.56 and a 52 week high of $72.51. The company has a quick ratio of 0.63, a current ratio of 0.82 and a debt-to-equity ratio of 0.77. The stock has a 50 day simple moving average of $65.11 and a 200-day simple moving average of $61.58. The company has a market cap of $85.23 billion, a PE ratio of 16.08, a PEG ratio of 0.97 and a beta of 0.57.
CVS Health (NYSE:CVS - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.63. CVS Health had a return on equity of 10.59% and a net margin of 1.39%. The firm had revenue of $94.59 billion during the quarter, compared to the consensus estimate of $93.07 billion. During the same period last year, the company earned $1.31 earnings per share. The company's revenue was up 7.0% on a year-over-year basis. As a group, research analysts expect that CVS Health Corporation will post 5.89 earnings per share for the current year.
Insider Buying and Selling at CVS Health
In related news, Director Guy P. Sansone purchased 1,570 shares of CVS Health stock in a transaction dated Thursday, June 5th. The stock was purchased at an average cost of $63.70 per share, for a total transaction of $100,009.00. Following the completion of the acquisition, the director directly owned 12,007 shares of the company's stock, valued at $764,845.90. The trade was a 15.04% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 1.22% of the stock is owned by insiders.
Wall Street Analyst Weigh In
A number of analysts recently commented on CVS shares. UBS Group raised their price target on CVS Health from $67.00 to $71.00 and gave the stock a "neutral" rating in a research note on Friday, May 2nd. Robert W. Baird raised their price target on CVS Health from $51.00 to $71.00 and gave the stock a "neutral" rating in a research note on Tuesday, April 15th. Mizuho raised their price target on CVS Health from $70.00 to $76.00 and gave the stock an "outperform" rating in a research note on Wednesday, April 9th. Wells Fargo & Company reaffirmed an "overweight" rating and issued a $84.00 price target (up previously from $76.00) on shares of CVS Health in a research note on Tuesday, May 6th. Finally, Barclays set a $79.00 price target on CVS Health and gave the stock an "overweight" rating in a research note on Monday, June 2nd. Two analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $75.06.
Check Out Our Latest Report on CVS
CVS Health Company Profile
(
Free Report)
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
Featured Articles
Before you consider CVS Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.
While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
